Publications by authors named "Rebecca T Rylance"
Article Synopsis
- Electrocardiographic abnormalities are common in patients with arrhythmogenic right ventricular cardiomyopathy and were analyzed over the long term in a study involving 353 patients and almost 7,000 ECGs.
- The study found that over time, there were notable changes in QRS voltage, R- and T-wave amplitudes, as well as increases in QRS duration, terminal activation duration, and QTc interval, indicating a progressive worsening of the condition.
- T-wave inversions observed before diagnosis were linked to a higher risk of future ventricular arrhythmias, suggesting these ECG abnormalities could serve as early indicators of the disease even if they don't meet the full diagnostic criteria.
Background: Previous studies have demonstrated an association between transplantation rate per center and postoperative mortality after heart transplantation. In 2011, Sweden centralized heart transplants and waiting lists, reducing the number of centers from 3 to 2. We aimed to assess the active waiting time and pre- and post-transplant mortality before and after centralization.
View Article and Find Full Text PDFObjectives: Our aim was to derive, based on the SWEDEHEART registry, and validate, using the Western Denmark Heart registry, a patient-oriented risk score, the SweDen score, which could calculate the risk of 1-year mortality following a myocardial infarction (MI).
Methods: The factors included in the SweDen score were age, sex, smoking, diabetes, heart failure and statin use. These were chosen a priori by the SWEDEHEART steering group based on the premise that the factors were information known by the patients themselves.
Aims: The VALIDATE-SWEDEHEART trial was a registry-based randomized trial comparing bivalirudin and heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention. It showed no differences in mortality at 30 or 180 days. This study examines how well the trial population results may generalize to the population of all screened patients with fulfilled inclusion criteria in regard to mortality at 30 and 180 days.
View Article and Find Full Text PDF